NASDAQ · Biotechnology

AVBP (AVBP) Stock

$30.84 -0.55% NASDAQ: AVBP Healthcare

Valuation

MetricValue
Price$30.84
Market Cap$1.44B
P/E Ratio-8.82
P/B Ratio4.29
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$35.49
52-Week Low$16.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-55.17%
ROA-34.72%
ROCE-57.98%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio12.81

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-9.0M$-37.0M$-75.0M$-94.0M$-178.0M
Net Profit$-52.0M$-37.0M$-69.0M$-80.0M$-166.0M
EPS$-40.44$-1.10$-2.17$-2.56$-4.32
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$43.0M$183.0M$163.0M$275.0M$333.0M
Total Liabilities$2.0M$8.0M$12.0M$17.0M$26.0M
Cash$37.0M$163.0M$150.0M$74.0M$46.0M
Borrowings$0$0$0$0$0

Latest News

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight PR Newswire · Jun 15, 2026 The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight PR Newswire · Jun 1, 2026 ArriVent BioPharma Reports First Quarter 2026 Financial Results GlobeNewswire · May 11, 2026 A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate Simply Wall St. · May 10, 2026 ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers GlobeNewswire · May 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-44.0M$-56.0M$-70.0M$-161.0M
Investing Cash Flow$-40.0M$0$0$-192.0M$-71.0M
Financing Cash Flow$0$0$-2.0M$1.0M$0
Net Cash Flow$37.0M$126.0M$-13.0M$-76.0M$-29.0M
Free Cash Flow$-13.0M$-44.0M$-56.0M$-70.0M$-161.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-9.42%
Quick Ratio13.95
Interest Coverage—
Return 1Y44.08%
Return 3Y—
Return 5Y—

Ownership

Insiders Held1.63%
Institutions Held96.03%
Institutions Float Held97.63%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC4,401,0832026-03-31
Infinitum Asset Management, LLC 4,148,9232026-03-31
HHLR Advisors, LTD3,929,1172026-03-31
Orbimed Advisors LLC.3,027,3282026-03-31
FMR, LLC3,016,1322026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARVN $8.02 -3.43% -6.94 $517.14M 0.00%
ATXSAstria Therapeutics, Inc. $12.58 +0.00% -7.40 $718.13M 0.00%
DAWNDay One Biopharmaceuticals, Inc. $21.53 +0.00% -20.70 $2.22B 0.00%
DNA $8.07 -0.19% -1.30 $527.50M 0.00%
ERAS $17.72 -2.42% -23.45 $6.15B 0.00%

About AVBP

AVBP is led by CEO Zhengbin Yao, employs 52 people, headquartered in US, publicly traded since 2024.

AVBP stock trades at $30.84 with a market capitalization of $1.44B. The stock is valued at a price-to-earnings (P/E) ratio of -8.82, price-to-book of 4.29, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $16.10 and $35.49, and currently trades 13.1% below its 52-week high.

On profitability, AVBP generates a return on equity (ROE) of -55.17%, return on capital employed of -57.98%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides